Tempest Therapeutics Inc (TPST) Stock Price, Quote & News

Company Profile

Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its clinical-stage lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The comp...

Industry: Biotechnology

Sector: Healthcare

Phone: 415 798 8589

Website: www.tempesttx.com

Address:

2000 Sierra Point Parkway, Suite 400, Brisbane, United States

brotherearl Sep. 8 at 3:29 PM

$TPST paper hooking on.. outward we are heading..

0 · Reply

ezimon Sep. 8 at 3:27 PM

$TPST wrong, ignore anything this dude posts. if he burps or says a word its the same thing, just sound.

1 · Reply

ezimon Sep. 8 at 3:26 PM

$TPST OK, but given that you are wrong what other wise "prophesies" do you have? Lets face mate, if you or I or anyone could predict with such accuracy what is going to happen we would not be here. We would have slaves feeding us grapes and wine and treating us like demigods!

1 · Reply

sanabu Sep. 8 at 3:24 PM

$TPST been following inflow vs outflow lately ,more like pump and dump

1 · Reply

ezimon Sep. 8 at 3:22 PM

$TPST no, it will have zero impact on TPST you talk rubbish

0 · Reply

Michl2000 Sep. 8 at 3:06 PM

$TPST got the impression that within the last trading days we only see remarkable trading volume in the first trading hour and sometimes in the late trade 🤔.

1 · Reply

sanabu Sep. 8 at 3:04 PM

$TPST Economic data coming out this week are not likely to be good and might be bad for markets, expect some dip

0 · Reply

Michl2000 Sep. 8 at 2:14 PM

$TPST

1 · Reply

MisplacedOkie Sep. 8 at 1:36 PM

$TPST it doesn't look like there's going to be a dip. Maybe all the paper hands are gone? Nah, we couldn't be that lucky.

2 · Reply

Ueberschlaefer Sep. 8 at 12:59 PM

$TPST there was no announcement at 8, 8:30, 9, so there was a dip. below $11. will sell off more throughout the day. we may see some buy-in before thursday since that's the announcement day for TPST.

0 · Reply

Tempest Reports Second Quarter 2025 Financial Results and Provides Business Update

Jun 30, 2025, 8:00 AM EDT - 2 months ago

Tempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in China

Jun 11, 2025, 8:00 AM EDT - 3 months ago

Tempest Announces $4.6 Million Registered Direct Offering of Common Stock

Jun 5, 2025, 8:00 AM EDT - 3 months ago

Tempest Receives Orphan Drug Designation from the European Medicines Agency for Amezalpat for the Treatment of Patients with HCC

May 13, 2025, 4:28 PM EDT - 4 months ago

Tempest Reports First Quarter 2025 Financial Results and Provides Business Update

Apr 28, 2025, 4:05 PM EDT - 4 months ago

Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting

Apr 21, 2025, 8:00 AM EDT - 5 months ago

Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP

Apr 9, 2025, 4:30 PM EDT - 5 months ago

Tempest Announces Plan to Explore Strategic Alternatives to Advance Promising Pipeline of Clinical Oncology Assets and Maximize Stockholder Value

Mar 27, 2025, 4:10 PM EDT - 5 months ago

Tempest Reports Year End 2024 Financial Results and Provides Business Update

Mar 25, 2025, 4:30 PM EDT - 5 months ago

Tempest Announces Amezalpat Poster Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Mar 13, 2025, 8:00 AM EDT - 6 months ago

FDA Study May Proceed Notice Received for Phase 2 Trial of TPST-1495 for the Treatment of Familial Adenomatous Polyposis (FAP)

Feb 10, 2025, 8:00 AM EST - 7 months ago

Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma

Feb 7, 2025, 4:30 PM EST - 7 months ago

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jan 6, 2025, 8:00 AM EST - 8 months ago

Tempest Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma (HCC)

Nov 25, 2024, 4:30 PM EST - 10 months ago

Tempest to Participate in the Piper Sandler 36th Annual Healthcare Conference

Nov 12, 2024, 4:21 PM EST - 10 months ago

Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update

Oct 10, 2024, 9:06 AM EDT - 11 months ago

Why Is Cancer Focused Tempest Therapeutics Stock Trading Higher On Thursday?

Oct 10, 2024, 7:01 AM EDT - 11 months ago

Tempest Announces Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line Hepatocellular Carcinoma Pivotal Trial

Sep 20, 2024, 4:30 PM EDT - 1 year ago

Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 5, 2024, 8:00 AM EDT - 1 year ago

Tempest to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 15, 2024, 8:00 AM EDT - 1 year ago

Tempest Announces Successful End-of-Phase 2 Meeting with FDA for Amezalpat (TPST-1120) to Treat First-Line Hepatocellular Carcinoma

Aug 8, 2024, 4:56 PM EDT - 1 year ago

Tempest Reports Second Quarter 2024 Financial Results and Provides Business Update

Jun 20, 2024, 9:43 AM EDT - 1 year ago

What's Going On With Cancer-Focused Tempest Therapeutics Stock On Thursday?

Jun 18, 2024, 6:22 PM EDT - 1 year ago

Tempest to Report New Data from Global Randomized Combination Study of Amezalpat (TPST-1120) in First-Line Hepatocellular Carcinoma

May 31, 2024, 3:45 PM EDT - 1 year ago

Glancy Prongay & Murray LLP Announces Investigation of Tempest Therapeutics, Inc. (TPST)

May 9, 2024, 4:29 PM EDT - 1 year ago

Tempest Reports First Quarter 2024 Financial Results and Provides Business Update

Apr 17, 2024, 1:26 PM EDT - 1 year ago

Tempest Therapeutics: Multiple 2024 Catalysts Make This A Must Watch

Apr 9, 2024, 8:00 AM EDT - 1 year ago

Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting

Apr 4, 2024, 8:00 AM EDT - 1 year ago

Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications

Mar 19, 2024, 4:25 PM EDT - 1 year ago

Tempest Reports Year End 2023 Financial Results and Provides Business Update

Mar 5, 2024, 4:30 PM EST - 1 year ago

Tempest Announces Upcoming Presentation of Preclinical Data for TPST-1120 in Renal Cell Carcinoma at the AACR Annual Meeting

Nov 20, 2023, 8:00 AM EST - 1 year ago

Tempest to Present at the 35th Annual Piper Sandler Healthcare Conference

Nov 8, 2023, 5:17 PM EST - 1 year ago

Tempest Reports Third Quarter 2023 Financial Results and Provides Business Update

Oct 13, 2023, 4:13 PM EDT - 2 years ago

Tempest Therapeutics shares end wild week with 8% drop

Oct 12, 2023, 12:49 PM EDT - 2 years ago

Tempest Therapeutics shares head back to earth after 4,000% gain

Oct 12, 2023, 11:26 AM EDT - 2 years ago

Top trending biotech stocks: ANVS, MTNB, AVTX, TPST

ANVS AVTX MTNB

Oct 11, 2023, 12:29 PM EDT - 2 years ago

Tempest Therapeutics' stock jumps 1,900% as liver-cancer treatment shows promise

Oct 11, 2023, 8:01 AM EDT - 2 years ago

Tempest Adopts Limited Duration Stockholder Rights Plan

Oct 11, 2023, 8:00 AM EDT - 2 years ago

Tempest Releases New Data Demonstrating Superiority of TPST-1120 Arm Across Multiple Study Endpoints in Randomized First-Line HCC Study

Oct 10, 2023, 4:05 PM EDT - 2 years ago

Tempest to Report New and Updated Data from Global Randomized Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma

Sep 19, 2023, 8:00 AM EDT - 2 years ago

Tempest Announces Expanded Role for Sam Whiting, M.D., Ph.D., as Chief Medical Officer and Head of Research and Development

Aug 10, 2023, 4:13 PM EDT - 2 years ago

Tempest Reports Second Quarter 2023 Financial Results and Provides Business Update

May 31, 2023, 4:05 PM EDT - 2 years ago

Tempest to Present at the Jefferies Global Healthcare Conference

May 25, 2023, 5:00 PM EDT - 2 years ago

Tempest to Present Phase 1 Monotherapy and Combination Data at ASCO for TPST-1495 in Patients with Advanced Cancers

May 10, 2023, 4:15 PM EDT - 2 years ago

Tempest Reports First Quarter 2023 Financial Results and Provides Business Update

Apr 27, 2023, 4:58 PM EDT - 2 years ago

Tempest to Report Early Results from Global Randomized Phase 1b/2 Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma

Apr 26, 2023, 6:41 PM EDT - 2 years ago

Tempest Announces TPST-1495 Poster Presentation at the 2023 ASCO Annual Meeting

Mar 22, 2023, 5:26 PM EDT - 2 years ago

Tempest Reports Year End 2022 Financial Results and Provides Business Update

Mar 14, 2023, 4:30 PM EDT - 2 years ago

Tempest to Present New Translational and Preclinical Data at the 2023 AACR Annual Meeting

Nov 22, 2022, 4:05 PM EST - 3 years ago

Tempest to Present at the Piper Sandler 34th Annual Healthcare Conference

brotherearl Sep. 8 at 3:29 PM

$TPST paper hooking on.. outward we are heading..

0 · Reply

ezimon Sep. 8 at 3:27 PM

$TPST wrong, ignore anything this dude posts. if he burps or says a word its the same thing, just sound.

1 · Reply

ezimon Sep. 8 at 3:26 PM

1 · Reply

sanabu Sep. 8 at 3:24 PM

$TPST been following inflow vs outflow lately ,more like pump and dump

1 · Reply

ezimon Sep. 8 at 3:22 PM

$TPST no, it will have zero impact on TPST you talk rubbish

0 · Reply

Michl2000 Sep. 8 at 3:06 PM

$TPST got the impression that within the last trading days we only see remarkable trading volume in the first trading hour and sometimes in the late trade 🤔.

1 · Reply

sanabu Sep. 8 at 3:04 PM

$TPST Economic data coming out this week are not likely to be good and might be bad for markets, expect some dip

0 · Reply

Michl2000 Sep. 8 at 2:14 PM

$TPST

1 · Reply

MisplacedOkie Sep. 8 at 1:36 PM

$TPST it doesn't look like there's going to be a dip. Maybe all the paper hands are gone? Nah, we couldn't be that lucky.

2 · Reply

Ueberschlaefer Sep. 8 at 12:59 PM

$TPST there was no announcement at 8, 8:30, 9, so there was a dip. below $11. will sell off more throughout the day. we may see some buy-in before thursday since that's the announcement day for TPST.

0 · Reply

Lisajane Sep. 8 at 12:42 PM

$TPST Maybe baby?

4 · Reply

YieldYeah Sep. 8 at 11:51 AM

$TPST Is anyone seeing this at premarket this morning? what could it mean? Both sites are showing no data for Tempest 😳

6 · Reply

Bungfolio Sep. 8 at 11:26 AM

$TPST https://www.usatoday.com/story/money/2025/09/06/home-depot-acquires-gms/86014040007/

1 · Reply

Ueberschlaefer Sep. 8 at 11:22 AM

$TPST this will drift back down to 10 or so today with no announcement. mon/thur are the traditional PR days for TPST. october is still the month in my opinion, mid month or later.

0 · Reply

FireFoxF10 Sep. 8 at 1:49 AM

$TPST wen rich? I have 4k shares and would like to retire. Thank you for your attention to this matter

3 · Reply

Bungfolio Sep. 7 at 11:51 PM

$TPST For future reference. Also adding more a lot of similarities in the charts. Draw your own conclusions

1 · Reply

th3_fail_k1ng Sep. 7 at 11:34 PM

$TPST why is everybody talking about a buyout? I'm going to arbitrarily ask a question and not do any actual looking on the thread to see what the reason could be that everyone believes there might be a buyout being announced in the very near future. I would rather just make everybody have to repeat themselves for the 50th time as opposed to being forced to scroll down just a couple of headlines on the thread to see what sparked the debate about is there going to be a buyout. Would you please waste your time and re-educate me I know you all already made a long list of posts that I could take the time to read but I would much rather if you just address me personally......TF

4 · Reply

Ssssssssssssscfg Sep. 7 at 10:46 PM

$TPST why is everyone talking about buyout price and what to do post buyout over the weekend as if there is some confirmation. Is there any news, I can’t find any.

3 · Reply

jyc990 Sep. 7 at 9:28 PM

$TPST after a buyout typically how long do we have before we have to sell our shares and realize a gain? Ideally I'd like to realize next year for tax purposes.

1 · Reply

WallStreetIsNotEasy Sep. 7 at 5:39 PM

$TPST Del Ray Beach, FLA ❤️

1 · Reply

thaboss8854 Sep. 7 at 4:48 PM

$TPST what do we prefer? A buyout or a reserve merger with a sub division of Roche, Bayer etc which means we might have more room for growth. We might see the same type of gains but we have the potential to gain more. But yeah I think Roche would be the buyer. They have done too much with TPST Also the deal has to be done in September and October at latest as there will be selling if it's too close to the deadline. They still need to do the voting and account for anything that might go sideways. So need a cushion for that. I think it should come very soon. Here are some summary of recent peculiar events. (Some points are alleged) There was an update on Roche TPST clinical trials and they also deem positive results People couldn't buy the shares as there were no shares available but later we could buy Schwab showed that it was halted but still allowed buying Things like this dont usually happen with a share. So load up when you can. They are probably preparing

5 · Reply

brunoq14 Sep. 7 at 3:28 PM

$TPST Is the FAP trial happening? It was only supposed to take about six months.

1 · Reply

Market Cap	48.80M
Revenue (ttm)	0.00
Net Income (ttm)	-41.84M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	89,400
Avg Vol	83,154
Day's Range	N/A - N/A
Shares Out	4.44M
Stochastic %K	79%
Beta	-1.93
Analysts	Sell
Price Target	$9.00